Vistagen Therapeutics (VTGN) Capital Expenditures (2010 - 2025)
Vistagen Therapeutics (VTGN) posted Capital Expenditures of $143000.0 for Q4 2025, up 350.88% sequentially from -$57000.0 in Q3 2025, and up 38.83% YoY from $103000.0 in Q4 2024.
Vistagen Therapeutics (VTGN) Capital Expenditures (2010 - 2025) Analysis & Trends
Vistagen Therapeutics has reported Capital Expenditures for 15 years, with the latest figure at $143000.0 in Q4 2025.
- Quarterly Capital Expenditures rose 38.83% year-over-year to $143000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $48000.0 (down 57.89% YoY) and the FY2024 annual result came in at $29000.0, down 94.51% from the prior year.
- Capital Expenditures rose to $143000.0 in Q4 2025 per VTGN's latest filing, from -$57000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $528000.0 in Q1 2023 and troughed at -$200300.0 in Q1 2022.
- A 5-year average of $49077.8 and a median of $24950.0 in 2021 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2022 and 2024: Capital Expenditures plunged 199400.0% in 2022, then jumped 472.22% in 2024.
- Over 5 years, Capital Expenditures stood at -$100.0 in 2021, then slumped by 199400.0% to -$199500.0 in 2022, then soared by 109.02% to $18000.0 in 2023, then surged by 472.22% to $103000.0 in 2024, then soared by 38.83% to $143000.0 in 2025.
- According to Business Quant data, Capital Expenditures over the past three periods registered $143000.0, -$57000.0, and $65000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.77 Bn | 131.91 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 65.36 Bn | 60.17 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.60 Bn | 54.47 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 251.02 Mn |
| 10 | Vistagen Therapeutics | 10.54 Mn | 10.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 143,000.00 |
| Dec 31, 2025 | 143,000.00 |
| Sep 30, 2025 | -57,000.00 |
| Sep 30, 2025 | -57,000.00 |
| Jun 30, 2025 | 65,000.00 |
| Jun 30, 2025 | 65,000.00 |
| Mar 31, 2025 | -103,000.00 |
| Mar 31, 2025 | -103,000.00 |
| Dec 31, 2024 | 103,000.00 |
| Dec 31, 2024 | 103,000.00 |
| Sep 30, 2024 | -75,000.00 |
| Sep 30, 2024 | -75,000.00 |
| Jun 30, 2024 | 75,000.00 |
| Jun 30, 2024 | 75,000.00 |
| Mar 31, 2024 | 11,000.00 |
| Mar 31, 2024 | 11,000.00 |
| Dec 31, 2023 | 18,000.00 |
| Dec 31, 2023 | 18,000.00 |
| Mar 31, 2023 | 528,000.00 |
| Mar 31, 2023 | 528,000.00 |